Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 29, 2022
Daily News
November 29, 2022
- KM Biologics to File COVID Jab in Japan Spring 2023: Official
November 29, 2022
- Obesity Society to Highlight Proper Use of Semaglutide If Label Expanded
November 29, 2022
- Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
November 29, 2022
- Limit Coverage of Off-Year Re-Pricing to Drugs with Large-than-Average Price Gap: LDP Proposal
November 29, 2022
- Sanofi’s Cemiplimab Backed for Approval, Third PD-1 Inhibitor in Japan
November 29, 2022
- MHLW to Report Responses to Zolgensma Paper Retraction on Dec. 12
November 29, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…